• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

达托霉素用于治疗肾移植受者的耐万古霉素屎肠球菌所致复杂性尿路感染。

Daptomycin for a complicated urinary tract infection with vancomycin-resistant Enterococcus faecium in a renal transplant recipient.

作者信息

Eden Gabriele, Burkhardt Olaf, Clajus Christian, Kielstein Jan T

机构信息

Department of Nephrology and Hypertension , Medical School Hannover , Hannover , Germany.

Department of Pulmonary Medicine , Medical School Hannover , Hannover , Germany.

出版信息

Clin Kidney J. 2012 Aug;5(4):350-1. doi: 10.1093/ckj/sfs076.

DOI:10.1093/ckj/sfs076
PMID:25874096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4393481/
Abstract

There is an increasing prevalence of urinary tract infection (UTI) caused by multiresistant gram-negative enteric bacilli such as extended-spectrum beta-lactamase as well as Gram-positive enterococci whose vancomycin-resistance can be as high as 25%. We report on a 68-year-old Caucasian female with a UTI caused by a vancomycin-resistant Enterococcus faecium, only tested to be susceptible to gentamycin, linezolid and daptomycin. Within a day after administration of the bactericidal daptomycin clinical and laboratory signs of infection regressed and graft function recovered. Our case suggests that daptomycin might be an effective alternative for UTI caused by vancomycin-resistant enterococci.

摘要

由多重耐药革兰氏阴性肠道杆菌（如超广谱β-内酰胺酶）以及万古霉素耐药率高达25%的革兰氏阳性肠球菌引起的尿路感染（UTI）患病率正在上升。我们报告了一名68岁的白种女性，她患有由耐万古霉素屎肠球菌引起的UTI，仅检测出对庆大霉素、利奈唑胺和达托霉素敏感。在给予杀菌性达托霉素一天内，感染的临床和实验室体征消退，移植功能恢复。我们的病例表明，达托霉素可能是耐万古霉素肠球菌引起的UTI的有效替代药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd52/4393481/a60046c7486a/sfs07601.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd52/4393481/a60046c7486a/sfs07601.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd52/4393481/a60046c7486a/sfs07601.jpg

相似文献

1
Daptomycin for a complicated urinary tract infection with vancomycin-resistant Enterococcus faecium in a renal transplant recipient.达托霉素用于治疗肾移植受者的耐万古霉素屎肠球菌所致复杂性尿路感染。
Clin Kidney J. 2012 Aug;5(4):350-1. doi: 10.1093/ckj/sfs076.
2
In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.达托霉素与利奈唑胺及万古霉素针对引起复杂性尿路感染的革兰氏阳性尿路病原体的体外活性，以及氨苄西林针对肠球菌的体外活性。
Chemotherapy. 2005 May;51(2-3):64-9. doi: 10.1159/000085611. Epub 2005 May 4.
3
Survival of Patients With Vancomycin-Resistant Enterococcus faecium Bacteremia Treated With Conventional or High Doses of Daptomycin or Linezolid Is Associated With the Rate of Bacterial Clearance.万古霉素耐药粪肠球菌菌血症患者的生存率与细菌清除率有关，而与达托霉素或利奈唑胺的常规剂量或高剂量治疗无关。
Crit Care Med. 2018 Oct;46(10):1634-1642. doi: 10.1097/CCM.0000000000003264.
4
Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).针对2005年在欧洲医疗中心分离出的耐甲氧西林葡萄球菌和耐万古霉素肠球菌测试达托霉素的抗菌活性。
BMC Infect Dis. 2007 Apr 18;7:29. doi: 10.1186/1471-2334-7-29.
5
1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.1,2,4-恶二唑类抗菌药物与达托霉素具有协同作用，并对耐万古霉素粪肠球菌表现出快速杀菌动力学。
J Antimicrob Chemother. 2018 Jun 1;73(6):1562-1569. doi: 10.1093/jac/dky064.
6
Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.评价替加环素对金黄色葡萄球菌和对万古霉素、达托霉素或利奈唑胺敏感性降低的肠球菌的抗菌活性。
J Antimicrob Chemother. 2016 Jan;71(1):152-5. doi: 10.1093/jac/dkv302. Epub 2015 Oct 16.
7
Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS).针对耐万古霉素肠球菌（VRE）引起的尿路感染（UTI）分离株的抗生素活性：2002年北美耐万古霉素肠球菌药敏试验（NAVRESS）的结果。
J Antimicrob Chemother. 2003 Sep;52(3):382-8. doi: 10.1093/jac/dkg352. Epub 2003 Jul 29.
8
Comparison of risk factors and outcomes of daptomycin-susceptible and -nonsusceptible vancomycin-resistant Enterococcus faecium infections in liver transplant recipients.肝移植受者中对达托霉素敏感和不敏感的耐万古霉素屎肠球菌感染的危险因素及结局比较
Transpl Infect Dis. 2018 Jun;20(3):e12856. doi: 10.1111/tid.12856. Epub 2018 Apr 16.
9
In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.人白蛋白或人血清的存在对达托霉素针对革兰氏阳性菌主要耐药表型菌株杀菌活性的体外影响。
J Antimicrob Chemother. 2007 Jun;59(6):1185-9. doi: 10.1093/jac/dkm078. Epub 2007 Apr 5.
10
Treatment options for vancomycin-resistant enterococcal infections.耐万古霉素肠球菌感染的治疗选择。
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.

引用本文的文献

1
A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections.头孢洛扎/他唑巴坦与哌拉西林/他唑巴坦治疗复杂性尿路感染的临床结局的荟萃分析。
Biomed Res Int. 2022 Aug 8;2022:1639114. doi: 10.1155/2022/1639114. eCollection 2022.

本文引用的文献

1
Safety of daptomycin in patients receiving hemodialysis.接受血液透析患者使用达托霉素的安全性。
Pharmacotherapy. 2011 Jul;31(7):665-72. doi: 10.1592/phco.31.7.665.
2
Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.静脉滴注达托霉素在持续不卧床腹膜透析中的药代动力学和药效学。
Clin J Am Soc Nephrol. 2011 May;6(5):1081-8. doi: 10.2215/CJN.08510910. Epub 2011 Mar 10.
3
Treatment of resistant enterococcal urinary tract infections.肠球菌耐药性尿路感染的治疗。
Curr Infect Dis Rep. 2010 Nov;12(6):455-64. doi: 10.1007/s11908-010-0138-8.
4
Vancomycin-resistant enterococcal urinary tract infections.万古霉素耐药肠球菌尿路感染。
Pharmacotherapy. 2010 Nov;30(11):1136-49. doi: 10.1592/phco.30.11.1136.
5
Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis.重症患者连续静脉-静脉血液透析时的达托霉素药代动力学。
Crit Care Med. 2011 Jan;39(1):19-25. doi: 10.1097/CCM.0b013e3181fa36fb.
6
Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study.重症监护病房急性肾损伤行延长透析的患者中达托霉素的剂量-一项药代动力学研究。
Nephrol Dial Transplant. 2010 May;25(5):1537-41. doi: 10.1093/ndt/gfp704. Epub 2009 Dec 22.
7
Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.慢性血液透析患者中单剂达托霉素的药代动力学。
Nephrol Dial Transplant. 2010 Apr;25(4):1279-84. doi: 10.1093/ndt/gfp655. Epub 2009 Dec 10.
8
Urinary tract infection in the renal transplant patient.肾移植患者的尿路感染
Nat Clin Pract Nephrol. 2008 May;4(5):252-64. doi: 10.1038/ncpneph0781. Epub 2008 Mar 11.
9
Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program.北美和欧洲耐万古霉素肠球菌的抗菌药物耐药性及分子流行病学：哨兵抗菌监测项目报告
Diagn Microbiol Infect Dis. 2007 Jun;58(2):163-70. doi: 10.1016/j.diagmicrobio.2006.12.022. Epub 2007 Mar 26.
10
In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.达托霉素与利奈唑胺及万古霉素针对引起复杂性尿路感染的革兰氏阳性尿路病原体的体外活性，以及氨苄西林针对肠球菌的体外活性。
Chemotherapy. 2005 May;51(2-3):64-9. doi: 10.1159/000085611. Epub 2005 May 4.